Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-4: Once-weekly Eloralintide in Adults With Knee Osteoarthritis and Overweight/Obesity
jRCT2071260001Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of eloralintide in knee osteoarthritis (OA), Overweight and obesity (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percent Change from Baseline in Body Weight and Change from Baseline in WOMAC Pain Subscale Score. Started Apr 2026; status: recruiting.
02
Drugs
eloralintide
03
Conditions
knee osteoarthritis (OA)Overweightobesity
Beyond the preview
Go deeper on jRCT2071260001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260001.